Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Temperature intolerance, Urticaria, Urticaria chronic
Clinical narrative: sense deficiencies with his immune system; Rheumatoid factor; stinging; itchy skin; hives; allergic to heat; sunburn; chronic Urticaria; Anhidrosis; sensitive skin; sweat glands disabled; heat rash; internal discomfort; Positive antinuclear Abs; Ck total above normal; ENA IGG above normal range; Hypertension; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP).  A 37-year-old male patient received BNT162b2 (BNT162B2), on 23Dec2021 as dose 3 (booster), single (Lot number: FL3198-PFIZER-2021) at the age of 37 years for covid-19 immunisation. The patient's relevant medical history included: "Never smoker" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1 Lot no-1111-20-EW0177, ), administration date: 28May2021, for COVID-19 Immunization; BNT162b2 (Dose 2 Lot no-1111-20-EW0168, ), administration date: 18Jun2021, for COVID-19 Immunization. The following information was reported: IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "sense deficiencies with his immune system"; RHEUMATOID FACTOR (non-serious), outcome "unknown"; PAIN (non-serious), outcome "unknown", described as "stinging"; PRURITUS (non-serious), outcome "unknown", described as "itchy skin"; URTICARIA (non-serious), outcome "unknown", described as "hives"; TEMPERATURE INTOLERANCE (non-serious), outcome "unknown", described as "allergic to heat"; SUNBURN (non-serious), outcome "unknown"; URTICARIA CHRONIC (non-serious), outcome "unknown", described as "chronic Urticaria"; ANHIDROSIS (non-serious), outcome "unknown"; SENSITIVE SKIN (non-serious), outcome "unknown"; SWEAT GLAND DISORDER (non-serious), outcome "unknown", described as "sweat glands disabled"; MILIARIA (non-serious), outcome "unknown", described as "heat rash"; DISCOMFORT (non-serious), outcome "unknown", described as "internal discomfort"; ANTINUCLEAR ANTIBODY POSITIVE (non-serious), outcome "unknown", described as "Positive antinuclear Abs"; BLOOD CREATINE PHOSPHOKINASE INCREASED (non-serious), outcome "unknown", described as "Ck total above normal"; BLOOD IMMUNOGLOBULIN G INCREASED (non-serious), outcome "unknown", described as "ENA IGG above normal range"; HYPERTENSION (non-serious), outcome "unknown". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pruritus, sunburn, urticaria chronic, anhidrosis, sensitive skin.  Additional information: On 23Dec2021, (Name withheld) was given a COVID-19 Booster dose shot at (address withheld). He started reacting and and sence deficiencies with his immune system with in 7-10 days after shot. He notified his regular Physician and she sent him for a drug test. In review she started nothing urgent was seen and that he should continue taking Zyrtec 2 times a day. His condition worsened nd started looking for help elsewhere include a change of Physician. He has seen multiple doctors (5-7 regarding this issue and symptoms seems to persist. Most recent lab work show below. All allergist- Lab work ordered show abnormal test result. Rheumatoid Factor. Doc recommended lab work be reviewed. He is reacting to stinging/itchy skin from previous Covid-19 booster shot since Dec2021. Body causing hives and allergies to heat condition/ skin burn. CU anhydrous stinging sensitives skin. Problem onset: sweat glands disabled, Heat rash internal discomfort from sun penetration and heat sensitive/burn to internal body and stinging feeling. Rheumatology confirms positives result which include: Positive Antinuclear Abs, CK Total value normal range, ENA IGG above normal range. Using due to sensitive feeling of skin. prescription prednisolone give 4 mg. Using cloves due to spike follow-up and itching Hyproxyciomos. The following true below 6 on more using from itching and online physicioms.